Identification of CXCL10 as a potential therapeutic target for primary nonresponders to infliximab with Crohn's disease
Infliximab (IFX), the mainstay of current treatment for moderate-to-severe Crohn's disease (CD), markedly improved clinical symptoms and quality of life for patients. However, not all patients can benefit from IFX. This study aims to identify new therapeutic targets for primary nonresponders through combination of transcriptomic and proteomic analyses.